PHIA Koninklijke Philips N.V.

Philips launches obstetrics monitoring solution to support clinicians and expectant mothers during COVID-19 pandemic

Philips launches obstetrics monitoring solution to support clinicians and expectant mothers during COVID-19 pandemic

June 12, 2020

  • Under new April 2020 FDA guidance [1], the Avalon CL Fetal and Maternal Pod and Patch are now available in the U.S., in addition to existing countries in Europe, Australia, New Zealand and Singapore, to support fetal and maternal monitoring
  • Integrated with Philips’ comprehensive obstetrical care portfolio, the new offering has the potential to reduce mother and clinician risk of exposure to COVID-19, in hospital and in the home
  • Solution complements Philips innovative Remote Patient Monitoring suite designed to transform care for at-risk populations

Amsterdam, the Netherlands –  (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced an addition to its remote patient monitoring suite supporting at-risk populations during the COVID-19 emergency. The new wireless Avalon CL Fetal and Maternal Pod and Patch aim to reduce unnecessary physical interactions between clinicians and patients, which is of particular importance during the COVID-19 pandemic. The patch is part of a broader innovative high-risk pregnancy solution which includes Philips perinatal analytics, and visualization software as well as an ultra-portable battery-operated fetal monitor. 

Up to half a million women may deliver their babies while infected with COVID-19 in 2020. Additionally, pregnant women who have not been diagnosed with COVID-19 are interested in ways they can minimize their time in a hospital to limit their exposure to the disease. While clinicians are treating COVID-19 patients in isolation rooms, and accommodating home visits and births when possible, properly managing patient care while reducing the risk of exposure for care providers requires tools that enable remote monitoring of vitals.

allow for continuous, non-invasive monitoring of maternal heart rate, fetal heart rate, and uterine activity with a single-use, 48-hour, disposable electrode patch placed on the mother’s abdomen. The patch is designed to be placed on the patient by a clinician only once, unlike traditional elastic belts and sensors that require frequent repositioning.

“Remote monitoring during labor has always provided multiple benefits to expectant mothers, including comfort, mobility, and flexibility. But during the COVID-19 pandemic, the need for mobile solutions during pregnancy is greater than ever,” said Peter Ziese, General Manager, Monitoring & Analytics at Philips. “Philips has been dedicated to providing the best quality care for expectant mothers for more than fifty years. This new solution builds on our commitment to provide integrated continuous monitoring capabilities for high risk pregnancies. With this new patch, clinicians now have access to an innovative tool to help monitor pregnant women during COVID-19, helping to deliver comfort to these mothers during a particularly stressful time.”  

“The fact that the new sensors are disposable and don’t require constant repositioning has been particularly useful for us in the peak of the COVID-19 wave in March and April in Lisbon,” said Prof. Dr. Diogo Ayres-de-Campos, University of Lisbon, and President-Elect of the European Association of Perinatal Medicine (EAPM).

The Philips OB solution consists of the , featuring Philips proprietary Smart Pulse technology, and an obstetrical information management system for continuous data flow to the EMR, which includes:

  • : single-use disposable patch and reusable pod placed on the expectant mother’s abdomen to capture fetal and maternal heart rate, and uterine activity through ECG and EMG signals, without the need for constant repositioning;
  • : provides cableless monitoring with the Avalon Fetal Monitors to give expectant mothers freedom to move during labor, while measuring up to three fetuses. The Avalon CL Wide Range Pod leverages the hospital’s wireless LAN installation to allow mothers to expand the area of ambulation, by extending monitoring of all cableless measurements to the full reach of the WLAN.;
  • : obstetrical surveillance and information management system designed for use from antepartum visit through labor, delivery, and postpartum care. Patient data automatically displays and streams to the electronic medical record (EMR). ISP Revision K in combination with IntelliVue XDS Remote Display functionality offers the ability to control the Fetal Monitor remotely.

The received CE Mark clearance in 2019 and is available in many EU countries [2], as well as Australia, New Zealand and Singapore.

Philips has a comprehensive portfolio of services and solutions which can help to support the delivery of high-quality care to COVID-19 patients. It includes secure, connected and intelligent approaches to diagnosis, treatment and predictive monitoring in the hospital, plus screening, remote patient monitoring and care at home. With healthcare under more pressure than ever before, Philips’ telehealth and AI-enabled data analytics can help support workflows, facilitate remote collaboration and optimize resources. Philips’ COVID-19-related solutions are designed for rapid deployment and scalability. For more information on how Philips is addressing COVID-19 globally, please visit the . 

[1] .

[2] The Avalon Fetal and Maternal Pod and Patch is available across Europe in the Benelux, DACH, UK&I, Nordics, CEE and Iberia markets. 

For more information, please contact:

Kathy O’Reilly

Philips Global Press Office

Tel:

Email:

Twitter:

Silvie Casanova

Philips North America

Tel:

E-mail:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at .



 

Attachments

EN
12/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips agrees to acquire SpectraWAVE Inc., advancing next-generation ...

Philips agrees to acquire SpectraWAVE Inc., advancing next-generation coronary intravascular imaging and physiological assessment with AI December 15, 2025 Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled angio-based FFR technology that delivers rapid, accurate coronary physiology assessment from a single angiogram [1] SpectraWAVE’s technologies have the potential to significantly increase adoption of corona...

 PRESS RELEASE

Philips reiterates timing of 2026 outlook

Philips reiterates timing of 2026 outlook December 4, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today reaffirmed that its 2026 outlook will be issued as planned on February 10, in line with the company’s previously communicated schedule. As previously guided, the company expects continued performance improvement with sequential comparable sales growth, expanded margins (despite tariff headwinds) and strong cashflow. The company continues to expect comparative sales growth to accelerate sequentially in 2026 towards mid-single-digit gro...

 PRESS RELEASE

Philips expands commercial availability of world’s first real-time AI-...

Philips expands commercial availability of world’s first real-time AI-enabled light-based 3D navigation solution for image-guided therapy December 1, 2025 Commercial availability expanded across Europe and the United StatesReal-time AI-enabled 3D device visualization powered by light instead of X-ray, improving navigation in complex endovascular proceduresLumiGuide seamlessly integrates with Azurion, Philips’ proven, world-leading image-guided therapy platform designed to drive procedural innovation across clinical domains Amsterdam, the Netherlands and Chicago, USA – (NYSE: PHG, AEX: PH...

 PRESS RELEASE

Philips launches Verida, world’s first detector-based spectral CT powe...

Philips launches Verida, world’s first detector-based spectral CT powered by breakthrough AI, to advance diagnostic precision November 30, 2025 Philips pioneered detector-based spectral CT, which has been widely adopted in clinical routine exams across anatomies, supported by over 800 peer-reviewed publications [1]CE-marked, 510k pending Verida CT [2] integrates AI across the imaging chain, providing superb image quality while accelerating workflow and reducing dose [3, 4] Amsterdam, the Netherlands and Chicago, USA – At RSNA 2025, (NYSE: PHG, AEX: PHIA), a global leader in health techno...

 PRESS RELEASE

Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MR...

Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MRI platform November 30, 2025 Major technology breakthrough combines advanced AI for clinical insights and accelerated workflow in new premium 3.0T MRI platform [1] Amsterdam, the Netherlands, and Chicago, USA – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today unveiled BlueSeal Horizon [1], an entirely new 3.0T MRI innovation platform that includes the industry’s first helium-free 3.0T magnet at . A pivotal advance in MRI innovation, helium-free [2] 3.0T is a major scientific achievement set to have s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch